Clinical trials
Prostate Cancer Screening clinical trials
Below are recruiting prostate cancer screening clinical trials, each written for real people, not researchers. We’re tracking 320 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07751133RecruitingPhase 3
Hormone therapy dosing study for metastatic prostate cancer
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
ManchesterAges 18 years+ - NCT07783282RecruitingPhase 1
How prostate cancer drugs affect a new medicine
This study looks at how a new medicine called fezolinetant is processed by the body when taken alongside common prostate cancer hormone treatments. It is an early-phase trial that helps researchers understand if there are any drug interactions, which could be important for future treatment options.
Plovdiv, Plovdiv ProvinceAges 50–75 - NCT07667400RecruitingPhase 1/Phase 2
Docetaxel plus SX-682 for advanced head and neck or prostate cancer
This trial studies a combination of the chemotherapy drug docetaxel and an investigational drug called SX-682 for people with certain advanced head and neck cancers or prostate cancer. The goal is to see if the combination is safe and effective.
Bethesda, MarylandAges 18–120 - NCT06925737RecruitingPhase 3
Study of I-DXd for metastatic prostate cancer
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.
Phoenix, ArizonaAges 18 years+ - NCT07824349RecruitingPhase 1
JUR-003 for metastatic prostate cancer
This trial tests an experimental drug called JUR-003 in people with prostate cancer that has spread to other parts of the body. It aims to see if the drug can shrink tumors or slow the cancer's growth.
Grand Rapids, MichiganAges 18 years+ - NCT04894188Recruiting
Hormone plus radiation before prostate surgery for high-risk cancer
This trial studies giving hormone treatment and radiation before prostate surgery to treat high-risk, locally advanced prostate cancer. It aims to improve cancer control by shrinking or controlling the tumor before removing it.
Douliu City/Huwei Township, Yunlin CountyAges 20–75 - NCT03753243RecruitingPhase 2
Pembrolizumab and hormone blocker before prostate surgery
This Phase 2 trial studies whether pembrolizumab plus a hormone “androgen axis” blocker taken before prostate surgery can improve outcomes for people with high-risk, non-metastatic prostate cancer. It’s designed for patients who are planning prostate removal with an extended lymph node dissection.
Portland, OregonAges 18 years+ - NCT05406999RecruitingPhase 2
Intense hormone treatment before prostate surgery for high-risk cancer
This Phase 2 trial studies giving strong hormone-based treatment before prostate surgery to shrink and control high-risk, locally advanced prostate cancer. It may help improve surgical success and reduce cancer spread risk, but it requires careful health checks and prior-treatment limits.
Nanjing, JiangsuAges 18–80 - NCT07860047RecruitingPhase 2
Peptide vaccine with antibody therapy for prostate cancer
This trial tests a combination of a personalized peptide vaccine and an antibody therapy for men with prostate cancer that has returned after initial treatment. The goal is to see if this approach can control the cancer without needing stronger hormone therapy.
Heidelberg, Baden-WurttembergAges 18–80 - NCT06387056RecruitingPhase 2
Gene-guided hormone therapy before prostate cancer surgery
This trial tests whether giving a combination of hormone treatments before surgery can improve outcomes for men with prostate cancer that has spread locally or to a few bone spots. It uses genetic testing to match participants with the most effective treatment.
Xiamen, FujianAges 18 years+ - NCT05646550RecruitingPhase 1
Antibody CC-1 for men with returning prostate cancer
This Phase 1 study tests an antibody drug (CC-1) for men whose prostate cancer has come back, based on rising PSA blood tests. It looks at safety and how the treatment affects cancer activity, especially whether it can help control early biochemical recurrence.
TübingenAges 18 years+ - NCT07853209RecruitingPhase 3
A study of a radioactive drug for men with metastatic prostate cancer
This study tests a new radioactive drug (called [177Lu]Ludotadipep) that targets a molecule on prostate cancer cells. It may help slow cancer growth in men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy.
Gyeonggi-doAges 19 years+ - NCT07831824RecruitingPhase 2/Phase 3
Imaging drug to find prostate cancer spread before or after treatment
This trial tests an imaging agent that helps find cancer that has spread beyond the prostate, either when first diagnosed or if it comes back after treatment. The goal is to see what dose works best for clear pictures.
Grand Rapids, MichiganAges 18 years+ - NCT05352178RecruitingPhase 3
Targeted treatment for few-spread prostate cancer spots
This Phase 3 trial tests whether treating only a small number of prostate cancer metastases can help people with “oligorecurrent” (limited repeat) prostate cancer. It may reduce cancer activity while avoiding broader whole-body treatment for some patients.
LeuvenAges 18 years+ - NCT07801664RecruitingPhase 2
Short course hormone therapy for prostate cancer
This trial tests a short course of hormone therapy (androgen deprivation therapy) for men with a certain type of prostate cancer that is considered high-risk. The goal is to see if a shorter treatment period can still control the cancer while reducing side effects.
New York, New YorkAges 18 years+ - NCT07790718Recruiting
Exercise program to prevent colorectal cancer after prostate radiation
This study tests whether an exercise program can help prevent colorectal cancer in men who have had pelvic radiation for prostate cancer. It involves using an iPhone app to track activity and attending exercise sessions.
Duarte, CaliforniaAges 40–80 - NCT06575257RecruitingPhase 2
Darolutamide and Hormone Therapy Before Prostate Surgery
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
Xi’an, ShanxiAges 18–75 - NCT07762911Recruiting
MRI-based prostate cancer screening follow-up
This study is a follow-up for men already in the VISIONING prostate cancer screening program. It uses MRI scans to check for prostate cancer over 5 more years, helping catch any changes early.
Basel, Canton of Basel-CityAges 50 years+ - NCT07745361RecruitingPhase 2
Study of MRT-2359 with apalutamide for prostate cancer
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05129605Recruiting
Prostate cancer genetic risk screening study for men
This study looks at your personal and family risk for prostate cancer and helps decide who should have extra screening like MRI. It may help you find cancer earlier if you are at higher genetic risk.
Boston, MassachusettsAges 35–74 - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Los Angeles, CaliforniaAges 18 years+ - NCT06636682RecruitingPhase 2
Vaccine for men with high-risk prostate cancer after surgery
This trial tests a personalized vaccine (FK-PC101) given after prostate removal surgery for men with high-risk prostate cancer. It aims to see if the vaccine can help prevent the cancer from coming back without the need for additional hormone therapy or radiation.
Chicago, IllinoisAges Any age - NCT07649122RecruitingPhase 3
PET Scan Imaging for Prostate Cancer Recurrence Detection
This study tests a new type of PET scan (a detailed imaging test) to find out if prostate cancer has come back after treatment. You'll receive an injection of a special tracer and then have a scan that takes pictures to help doctors locate any cancer.
Nanjing, JiangsuAges 18 years+ - NCT07650240RecruitingPhase 2
PSMA Therapy and Hormone Treatment for Early-Stage Prostate Cancer Spread
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
Rochester, MinnesotaAges 18 years+
Hear when a new Prostate Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer screening?
- Yes. Clin2 currently lists 320 recruiting prostate cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.